Register and share your invite link to earn from video plays and referrals.

mon
@moninvestor
Stock Market Commentator. High risk/Small-cap investor/trader. Not Financial Advice. Opinions Only. I am ONLY on X & Substack. Long - $IREN, $HIMS & $ONDS.
Joined April 2022
112 Following    56K Followers
There's a clear pattern in the moves $HIMS has made lately, and it shows where Andrew Dudum is taking the company. Hims is becoming the platform people use to manage their health throughout their whole lives. First came the GRAIL partnership, which put Galleri cancer screening on the platform at $250 off the $949 list price for Labs members. One blood draw looks for a signal from more than 50 types of cancer. Now Hims has invested in Arboretum, a genetic testing company that launched this week with a $30M Series A, with Hims in the round alongside GV and Amgen. Arboretum's tests look at inherited disease risk. The results show doctors who needs earlier screening, closer monitoring or a particular treatment. Finding the inherited condition behind very high cholesterol, for example, means treatment can start earlier and the risk of heart disease comes down. That is how genetic testing turns into more personalised care. Hims already has the base for this. Labs launched in November 2025 with blood testing through Quest Diagnostics, and Dudum has said he sees it eventually becoming a $1B business. Hims will keep adding to that: genetic results, blood tests, medical history and ongoing treatment in one place, with a care plan that changes as the customer's health changes. Very bullish for long-term.
Show more
Today, I’m so proud to share that we're a strategic investor in Arboretum LifeSciences, a next-generation molecular information company. They’re combining genetic testing and AI to scale precision medicine to more conditions and more people. Since meeting the Arboretum team, I have been looking for ways to be a part of getting their innovation into more hands for one simple reason. Giving people the tools to understand their risk before symptoms develop is how you transform a sickcare system into a healthcare system. Understanding your own risk should be a normal part of care, not the exception. It’s the future of health that I believe in and it’s what Hims & Hers is all about. Health that gets smarter over time, adapts with you, and puts actionable information in your hands. This goes beyond rare diseases and can fundamentally change how common conditions like heart disease, diabetes, and neurodegeneration are managed. Today, Arboretum is working with health systems and their providers, and I’m excited for the day that this kind of innovation extends beyond the traditional system (more to come here from us). Congrats to Anthony, Clare, and the entire Arboretum team!
Show more